Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
Pazopanib Maintenance Phase II
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 1
- Registration Number
- NCT02207309
- Locations
- 🇩🇪
Ludwig-Maximilians University of Munich, Klinikum Großhadern, Munich, Bavaria, Germany
Pazopanib Vs. Pazopanib Plus Gemcitabine
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 58
- Registration Number
- NCT02203760
- Locations
- 🇩🇪
Universitätsklinikum Bonn, Bonn, Germany
🇩🇪Helios Klinikum Berlin-Buch, Klinik für Onkologie und Paliativmedizin, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum, Bad Saarow, Germany
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT02204371
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 16
- Registration Number
- NCT02193152
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 140
- Registration Number
- NCT02180867
- Locations
- 🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
Pazopanib Tolerability When Given With Food
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 78
- Registration Number
- NCT02138526
- Locations
- 🇳🇱
RadboudUMC, Nijmegen, Gelderland, Netherlands
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT02113826
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Optimizing Pazopanib Exposure in RCC Patients
- Conditions
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
- Target Recruit Count
- 6
- Registration Number
- NCT02089802
- Locations
- 🇩🇪
Private Practice Kamann, Leipzig, Sachsen, Germany
🇩🇪Gesundheitszentrum Holzminden, Holzminden, Niedersachsen, Germany
🇩🇪Private Practice Geiges, Berlin, Germany
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 96
- Registration Number
- NCT02066285
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸H. Son Espases, Palma De Mallorca, Islas Baleares, Spain
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 21
- Registration Number
- NCT02055690
- Locations
- 🇬🇧
University Collage London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Newcastle Upon Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.